CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Cancer Immunol Immunother
; 64(1): 105-12, 2015 Jan.
Article
em En
| MEDLINE
| ID: mdl-25233793
ABSTRACT
No second-line treatment significantly prolongs the survival of malignant mesothelioma patients who have a high unmet medical need. Here, we comment on the therapeutic potential of cytotoxic T-lymphocyte-associated protein (CTLA)4-blockade by the anti-CTLA4 monoclonal antibody (mAb) tremelimumab of refractory malignant mesothelioma patients. We also focus on the critical role of an accurate tumor assessment in the course of treatment with immunomodulating mAb. Finally, treatment with potentially effective, second-generation checkpoint(s) inhibiting mAb, as well future combination strategies in this deadly disease, will be discussed.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T Citotóxicos
/
Antígeno CTLA-4
/
Neoplasias Pulmonares
/
Mesotelioma
/
Anticorpos Monoclonais
/
Antineoplásicos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Cancer Immunol Immunother
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
NEOPLASIAS
/
TERAPEUTICA
Ano de publicação:
2015
Tipo de documento:
Article